• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Adaptimmune Ther ADR (NQ: ADAP )

    1.050 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 20
    Open 1.050
    Bid (Size) 1.050 (9)
    Ask (Size) 1.120 (2)
    Prev. Close 1.050
    Today's Range 1.050 - 1.050
    52wk Range 0.4200 - 2.050
    Shares Outstanding 1,480,950,456
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
    Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader... 
    Via Newsfile
    Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
    Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
    Via Newsfile

    Performance

    YTD
    +40.75%
    +40.75%
    1 Month
    -28.57%
    -28.57%
    3 Month
    +47.89%
    +47.89%
    6 Month
    +57.89%
    +57.89%
    1 Year
    -24.46%
    -24.46%

    More News

    Read More
    Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Adaptimmune Therapeutics Earnings Preview
    Via Benzinga
    Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023
    Via InvestorPlace
    Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
    Via Newsfile
    Topics Economy
    Exposures Product Safety Supply Chain
    Earnings Scheduled For March 6, 2024
    Via Benzinga
    Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
    Via Newsfile
    Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
    Via Newsfile
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
    Via Newsfile
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
    Via Newsfile
    Exposures Product Safety
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
    Via Newsfile
    Exposures Product Safety
    Adaptimmune Receives Transfer of IND for Lete-cel Program
    Via Newsfile
    Adaptimmune Reports Third Quarter Financial Results and Business Update
    Via Newsfile
    Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
    Via Newsfile
    Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
    Via Newsfile
    Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
    Via Newsfile
    Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
    Via Newsfile
    Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
    Via Newsfile
    Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
    Via Newsfile
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.